Name: Latest research reports of Cohance Lifesciences Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Cohance Lifesciences Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Cohance Lifesciences Ltd.

NSE: COHANCE | BSE: 543064 | ISIN: INE03QK01018 | Industry: Pharmaceuticals
| Expensive Performer

889.9500 -8.40 (-0.94%)

NSE Oct 17, 2025 15:31 PM

Near 52W Low of ₹856.00

Volume: 155.5K

Cohance Lifesciences Ltd.

29 May 2025

889.95

-0.94%

Cohance Lifesciences (BUY): To remain on a high growth trajectory

Buy: Cohance Lifesciences Ltd.

Target

BOB Capital Markets Ltd.

4QFY25 consolidated proforma sales were 11.4% above our estimates; EBITDA/APAT was -0.4% and -5.9% below estimates

Mutual Funds have increased holdings from 8.90% to 16.49% in Sep 2025 qtr.